ADMA Stock Cash Flow Statements

ADMA Biologics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

ADMA Biologics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2010-06-02	2009-03-31

cash flows from operating activities:
net income	34,218,000	26,904,000	111,896,000	35,909,000	32,062,000	17,806,000	-17,644,533	2,565,055	-6,370,707	-6,788,815	-12,231,683	-14,899,504	-13,764,906	-25,007,857	-16,649,420	-17,712,954	-18,905,303	-18,379,941	-19,407,774	-16,917,453	-20,178,091	-19,245,230	-10,561,031	-11,438,459	-13,211,872	-13,067,955	-18,037,987	-15,135,485	-14,747,831	-17,822,142	-12,982,802	-15,202,715	-9,036,495	-6,536,963	-4,559,108	-4,331,239	-6,012,335	-4,612,469	-4,582,653	-5,102,424	-4,679,318	-3,605,535	-3,563,357	-3,384,689	-3,961,245	-5,903,872	-4,701,208	-2,688,947	-4,895,444	-3,241,647	-2,251,537	-3,245,747	-1,206,715	-597,314	-4,810	-3,820
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	2,058,000	1,969,000	1,944,000	1,940,000	2,047,000	2,114,000	2,108,950	2,092,508	2,097,577	2,032,965	1,936,877	1,861,992	1,724,283	1,590,217	1,517,716	1,422,164	1,325,994	1,229,628	1,232,509	1,035,293	885,652	788,838	828,598	818,128	806,092	805,330	923,902	847,057	845,898	829,541	1,461,036	836,071	277,132	118,062	117,874	117,308	116,001	118,393	117,192	117,930	117,577	117,122	96,790	54,199	48,564	48,299	51,558	54,887	60,575	43,613	41,346	48,896	46,112	45,735
loss on disposal of fixed assets			74,000	8,000	1,000	23,000	71,053	92,851	0	18,096	418,128	5,770	638	2,000	140,282	2,344	77,354	781	69,219	8,960	2,542	976				391	108,990	10,741			5,989	0	0	4,155
deferred income tax provision	1,620,000	3,425,000
stock-based compensation	4,963,000	4,624,000	5,433,000	3,179,000	2,863,000	2,141,000	1,745,155	1,694,641	1,637,038	1,110,166	1,068,602	1,313,494	1,191,047	1,641,388	1,213,393	688,274	805,189	781,397	688,182	774,784	715,608	676,548	636,108	650,670	726,736	637,263	595,532	577,581	535,391	514,784	508,689	505,730	311,363	235,877	253,986	262,963	310,945	422,180	489,385	447,932	386,661	387,069	327,060	327,060	360,134	234,200	221,759	225,221	222,771	218,544
amortization of debt discount	160,000	190,000	219,000	252,000	227,000	253,000	698,210	721,040	686,861	487,889	493,542	981,066	342,219	584,842	503,231	485,991	464,357	443,794	438,084	469,612	445,021	429,711	460,741	379,126	95,714	244,767	295,490	283,536	269,288	255,847	225,999	181,179	184,136	190,253	194,065	188,380	160,951	133,547	131,226	127,547	48,591	46,271	38,196	34,112	32,391	28,498	24,720	23,858	22,782	20,344
loss on extinguishment of debt											0	0	0	6,669,941									0	0	0	9,962,495													0	0
amortization of license revenue			-36,000	-36,000	-35,000	-36,000	-35,875	-35,708	-35,709	-35,708	-35,709	-35,708	-35,709	-35,708	-35,709	-35,708	-35,709	-35,708	-35,709	-35,708	-35,709	-35,708	-35,709	-35,708	-35,709	-35,708	-35,709	-35,708	-35,709	-35,708	-35,709	-35,708	-35,709	-35,708		-35,708	-35,708	-35,709		-31,184	-18,889	-18,889	-18,889	-18,889	-18,889	-18,889	-18,889	-18,889
changes in operating assets and liabilities:
accounts receivable			141,000	-20,027,000	19,508,000	-22,200,000	3,897,632	5,412,930	-10,213,116	-11,013,446	5,397,337	-2,018,539	6,745,778	2,947,233	-8,184,236	3,151,973	-8,182,564	-2,124,740	-6,902,754	179,629	593,669	-3,637,915	3,845,562	-2,228,818	-3,776,259	82,037	2,734,353	-329,600	-139,592	222,552	-2,380,345	792,464	-1,452,335	178,089	309,504	-500,816	117,235	-19,482	276,147	-678,116	-171,056	32,518	178,210	241,342	-319,090	-484,423	335,091	-98,173	89,409	-287,215	22,785	158,199
inventories			1,566,000	8,009,000	-2,078,000	-4,826,000	-9,789,942	-1,336,042	2,204,810	-704,826	-366,414	-16,838,175	-6,929,149	-14,422,219	-10,601,217	-14,423,128	-5,553,543	-12,610,601	-11,783,070	-13,751,180	-3,712,546	775,932	-12,779,396	-16,695,588	-5,149,838	-25,310	-4,738,735	-1,630,466	191,834	189,379	790,790	-268,238	355,112	-288,346	-402,412	-408,408	-160,087	-603,466	-614,959	-377,918	-511,962	-232,171	-256,206	-339,955	-128,109	684,566	-463,985	-289,917	92,111	258,326	-255,906	193,354
prepaid expenses and other current assets			1,516,000	-4,021,000	-1,783,000	1,593,000	-226,691	111,281	-840,055	716,465	277,338	27,445	119,373	-1,180,056	1,519,801	-157,183	100,745	-2,756,142	739,955	907,006	161,917	-2,321,751	-817,255	-119,666	452,881	-289,134	-460,214	300,331	271,848	-652,474
deposits and other assets		120,000	426,000	-343,000	914,000	-982,000	2,300,849	-183,668	-1,326,413	289,232	-73,288	-489,021	-712,895	1,397,672	-961,790	-668,758	-164,375	19,718	-122,414	208,860	-203,663	-79,532	3,287	-14,145	-60,812	179,644
accounts payable	9,267,000	142,000	3,942,000	1,618,000	-1,857,000	447,000	4,993,769	-9,907	-871,958	-272,904	-11,968,415	13,809,757	-2,727,085	1,685,724	-4,853,432	11,115,376	-5,985,388	1,079,144	3,093,935	1,070,112	-2,242,576	-22,356	214,689	2,171,758	1,308,354	-420,601	632,710	2,166,602	-2,617,038	-202,754	-2,416,030	3,465,071	423,261	1,339,764	-212,540	-344,727	657,032	377,061	-3,241	617,405	-235,640	-69,866	-672,025	104,013	-424,150	54,383	1,185,008	323,817	-220,185	320,340	167,909	99,893
accrued expenses			6,426,000	-191,000	-5,965,000	772,000	2,655,622	136,001	6,092,192	-1,353,815	6,867,379	2,128,814	313,905	-1,775,526	2,815,121	2,545,686	3,823,577	-843,043	784,343	2,218,177	2,329,886	-1,930,591	-520,010	1,855,952	232,952	-762,541	-606,019	458,118	466,245	88,640	-663,217	-106,440	1,544,777	-160,637	560,558	220,298	-57,422	-306,462	18,965	555,872	-259,888	-514,564	680,570	314,835	-169,849	526,381	-19,259	89,666	76,476	-70,412	174,952	323,001
other current and non-current liabilities			-294,000	-1,269,000	-258,000	677,000	-229,655	-268,336	-105,458	-187,551	-136,823	-110,424	-143,927	-111,064	111,028	173,536	-32,571	-33,413	-22,145	-20,179	-46,185	-45,882	-52,598	-46,887	-20,587	-70,442	-16,959	-59,361	43,018	207,736
net cash from operating activities			50,216,000	25,028,000	45,646,000	-2,218,000	17,595,952	11,985,078	-6,058,756	-14,722,274	-7,379,315	-13,284,761	-12,830,768	-26,013,413	-33,465,232	-13,412,387	-32,262,237	-33,229,126	-32,219,436	-23,852,087	-21,284,475	-24,646,960	-19,652,036	-23,630,332	-18,623,952	-14,287,184	-18,793,124	-12,543,405	-14,908,039	-16,434,114	-13,358,629	-9,739,371	-8,775,348	-5,398,426	-3,613,678	-4,683,188	-4,804,177	-5,167,930	-4,078,209	-2,673,053	-4,446,367	-4,220,775	-2,902,433	-2,465,868	-4,296,279	-5,040,330	-2,959,763	-2,225,662	-2,626,958	-3,074,771	-1,807,050	-2,101,188	-996,858	-1,998,699	-3,910	-4,420
capex			-2,757,000	-1,056,000	-2,066,000	-2,347,000	-1,197,214	-756,557	-872,633	-1,944,596	-3,748,521	-3,380,481	-3,940,084	-2,842,085	-3,675,854	-2,788,669	-4,475,574	-2,571,161	-3,598,321	-2,885,075	-4,168,408	-2,074,876	-1,594,296	-1,971,867	-135,222	-110,453	-819,006	-230,219	-497,129	-549,246	-2,009,871	-569,900	-92,973	-3,584	-10,024	-5,352	-40,597	-17,437	4,496	-8,875	-7,508	-14,186	-556,288	-1,396,472	-258,543	-111,948	-5,459	-16,367	-108,735	-66,074	0	0	0	0	0	0
free cash flows			47,459,000	23,972,000	43,580,000	-4,565,000	16,398,738	11,228,521	-6,931,389	-16,666,870	-11,127,836	-16,665,242	-16,770,852	-28,855,498	-37,141,086	-16,201,056	-36,737,811	-35,800,287	-35,817,757	-26,737,162	-25,452,883	-26,721,836	-21,246,332	-25,602,199	-18,759,174	-14,397,637	-19,612,130	-12,773,624	-15,405,168	-16,983,360	-15,368,500	-10,309,271	-8,868,321	-5,402,010	-3,623,702	-4,688,540	-4,844,774	-5,185,367	-4,073,713	-2,681,928	-4,453,875	-4,234,961	-3,458,721	-3,862,340	-4,554,822	-5,152,278	-2,965,222	-2,242,029	-2,735,693	-3,140,845	-1,807,050	-2,101,188	-996,858	-1,998,699	-3,910	-4,420
cash flows from investing activities:
purchase of property and equipment			-2,757,000	-1,056,000	-2,066,000	-2,347,000	-1,197,214	-756,557	-872,633	-1,944,596	-3,748,521	-3,380,481	-3,940,084	-2,842,085	-3,675,854	-2,788,669	-4,475,574	-2,571,161	-3,598,321	-2,885,075	-4,168,408	-2,074,876	-1,594,296	-1,971,867	-135,222	-110,453	-819,006	-230,219	-497,129	-549,246	-2,009,871	-569,900	-92,973	-3,584	-10,024	-5,352	-40,597	-17,437	4,496	-8,875	-7,508	-14,186	-556,288	-1,396,472	-258,543	-111,948	-5,459	-16,367	-108,735	-66,074
acquisition of intangible assets			7,000	-42,000	-299,000	-15,000
net cash from investing activities			-2,750,000	-1,098,000	-2,365,000	-2,362,000	-1,407,214	-756,557	-872,633	-1,944,596	-3,748,521	-3,380,481	-3,940,084	-2,842,085	-3,675,854	-2,788,669	-4,475,574	-2,571,161	-3,598,321	-2,885,075	-4,168,408	-2,072,876	-1,594,296	-1,971,867	-135,222	-110,453	-819,006	-230,219	-497,129	-549,246	-2,009,871	-569,900	12,652,027	5,141,600	5,626,483	238,920	-8,616,582	3,655,762	5,400,680	4,157,117	-4,425,647	-6,873,725	1,110,666	-1,402,524	-4,369,080	620,195	-2,940,643	-16,367	-108,735	-66,074	-35,332	-27,370
cash flows from financing activities:
principal payments on term loan
proceeds from issuance on revolver
prepayment penalties on repayment of debt
taxes paid on vested restricted stock units			-644,000	-1,158,000	-693,000	-2,476,000	-340,450	-208,638	-224,966	-640,946	-2,067,543	-429,982	-309,948	-91,367	0	-2,287	0	-59,311
net proceeds from the exercise of stock options	2,064,000	101,000	443,000	5,691,000	331,000	1,029,000	8,461
payment of end of term fee																								0	0	-2,760,000
net cash from financing activities			-31,026,000	-25,467,000	-362,000	-1,447,000	-38,993,961	415,355	240,115	-650,509	62,743,358	-843,791	-319,041	47,271,326	53,819,634	8,202,668	17,181,060	41,844,844	32,063,864	10,631,085	-1,694	101,203,400	-7,685	-7,558	75,840,805	4,177,063	-507	-12,862	42,939,306	-4,377	50,374,683	-1,663,347	13,154,402	-1,115,113	-3,913	-198,930	17,044,800	-3,659	-59,279	-128,138	129,665	10,459,660	5,039,272	-49,114	16,431	4,788,617	26,669,840	-31,407	68,655	925,690	3,657,657	-38,833	-299,031	16,150,756	0	6,500
net increase in cash and cash equivalents			16,440,000	-1,537,000					-6,691,274	-17,317,379			-17,089,893	18,415,828	16,678,548	-7,998,388	-19,556,751	6,044,557	-3,753,893	-16,106,077	-25,454,577	74,483,564		-25,609,757	57,081,631	-10,220,574	-19,612,637	-12,786,486			35,006,183	-11,972,618																			1,815,275	-2,167,391	-1,352,040	14,152,057	-3,910	2,080
cash and cash equivalents - beginning of period	0	103,147,000		0	0	51,352,000		0	0	86,521,542		0				0	0	55,921,152														0	0	9,914,867		0	0	10,440,959		0	0	17,199,030		0	0	26,149,477		0	0	12,535,672
cash and cash equivalents - end of period	18,660,000	71,625,000		-1,537,000	42,919,000	45,325,000		11,643,876	-6,691,274	69,204,163		-17,509,033	-17,089,893	69,504,946		-7,998,388	-19,556,751	61,965,709		-16,106,077	-25,454,577	101,235,699										-11,972,618	17,031,081	8,542,928		-4,643,198	3,624,041	8,925,132		1,355,926	-8,742,349	16,564,190		-3,917,506	-8,648,928	26,517,959		-2,273,436	-2,667,038	10,320,517
adjustments to reconcile net income to net cash provided used in operating activities:
net decrease in cash and cash equivalents						-6,027,000																								-16,987,737				-1,371,939	2,008,892			-1,515,827	1,263,192	1,355,926				-3,917,506
deferred income tax benefit
interest paid in kind							877,408	992,432	986,182	979,978	973,814	978,272
principal payments on notes payable											0	0	0	-100,000,000									0	0	0	-30,000,000					-15,555,556	-1,666,666
proceeds from issuance of common stock, net of offering expenses															53,828,426	8,213,602	17,189,560	41,912,515					0	0			0	-1,280
proceeds from issuance of note payable											0	0	0	151,750,000					15,000,000	0	0	12,500,000	0	0	27,500,000	45,000,000
payments on finance lease obligations							-972	0	-6,465	-9,563	-9,403	-9,247	-9,093	-8,941	-8,792	-8,647	-8,500	-8,360	-8,220	-8,083	-7,949	-7,816	-7,685	-7,558	-7,432	-7,308
payment of deferred financing fees											0	-404,562	0	-2,378,366
cash and cash equivalents - beginning of year														51,089,118
cash and cash equivalents - end of year
repayment of notes payable
payment of debt refinancing fees											0	0	0	-2,000,000									0	0	0	-6,499,867
proceeds from the exercise of stock options																			0	0	6,255	7,177	0	0			6,679				0
gain on extinguishment of debt
proceeds from the sale of property and equipment																			0	0	0	2,000
(gain) loss on extinguishment of debt
gain on transfer of plasma center assets
payment of end of end of term fee
payment of debt issuance costs																							0	0	-123,899	-1,555,762					-1,475,331	0
cash and cash equivalents, including restricted cash - beginning of year
adjustments to reconcile net income to net
cash from operating activities:
deferred revenue																																							0								0	0
proceeds from the issuance of common stock, net of offering expenses																				10,639,168	0	88,704,039
cash and cash equivalents, including restricted cash - beginning of period																				0	0	26,752,135		0	0	26,754,852		0	0	48,607,574
changes in operating assets and liabilities, net of acquisition:
payments of leasehold improvement loan																											0	-10,844	-4,476	-4,377	-4,280	-4,185	-4,092	-4,002	-3,913	-3,826	-3,741	-3,659	-3,578	-3,498	-3,420	-3,345	-3,271	-3,198	-3,128	-3,057	-2,990	-2,924	-2,859	-2,796	-1,829	-2,693	-2,633	-2,575
cash and cash equivalents, including restricted cash - end of year
loss on disposal of property and equipment																								18,229
gain on transfer of plasma assets																								0	-1	-11,527,420
cash and cash equivalents, including restricted cash - end of period																								-25,609,757	57,081,631	16,534,278		-12,786,486	27,534,138	31,619,837
asset impairment charge
sales of short-term investments																															0	0	245,000	5,145,184				3,673,199
cash acquired in acquisition transaction																															0	0
proceeds from issuance of related party note payable																															0	0
payments on capital lease obligations																											-7,186	-7,066
other assets																												3,249	6,150	-29,515	240,636	-248,239	-472,891	-2,400									0	0	-20,689	6,103	460,648	-8,644	-54,314	195,361		0
other current liabilities																															-8,041	11,505
purchase of short-term investments																																				244,272			5,396,184	4,165,992	-4,418,139	-6,859,539	1,666,954	-6,052
cash and cash equivalents - end of year, including restricted cash
prepaid expenses																																329,949	-866,059	-432,932	167,744	156,401	106,851	-633,883	155,757	132,543	214,030	-469,771	142,076	109,223	202,713	-298,868	-75,312	143,542	284,482	-543,681	81,835	118,568
deferred rent liability																																		-7,640	-7,640	-7,640	-7,640	-7,640	-7,640	-7,640	-7,640	68,382	-5,547	-5,548	-5,547	-5,548	-5,548	-5,548	-5,547	-5,548	-5,548	-5,547
principal payments on note payable																																		-1,111,111
supplemental information:
cash paid for interest																																		424,470	425,818	422,947	353,247	328,223	319,207	217,329	465,874	324,378	223,822	225,162	230,293	106,250	107,431	108,611	105,305	61,389		0	0	3,820
supplemental disclosure of noncash financing activities:
accrued equity issuance costs																																					168,646	3,554		-116,115	-65,619	219,622	38,375	-28,652			-26,483						-254,393	279,394
warrant liability																																							0	0	0	-67,860	30,160	14,616	34,800	-5,220	17,278	-2,813	-21,027	-36,728
amortization of deferred financing costs																																							0	0	16,353	23,364	31,520	33,187	31,515	29,555	27,196	26,278	25,124	20,640
payment-in-kind interest																																							0	0	50,432	74,104	57,011	50,261	49,468	19,505
amortization of license and other revenue
purchases of short-term investments
redemptions of short-term investments
proceeds from oxford note payable																																			0	0			0	0
proceeds from issuance of common stock																																			0	1,072,259			0	-136,003	-69,622	10,463,005
proceeds from stock options exercised																																							1
repayment of hercules note payable																																							0	0
prepayment penalty of early extinguishment of note payable																																							0
payment of hercules end of term fee																																							0	0
equity issuance costs																																			0								42,543	-45,916
reclassification of equity issuance costs to additional paid-in capital																																										11,999										0	0	421,077
warrants issued in connection with note payable																																			0	0			0	0			182,816	0	0	219,588
end of term liability in connection with note payable																																			0				0
elimination of warrant liability																																							0	0	0	408,900
accrued interest																																							0	0	-114,715	9,051	31,998	365	-8,296	45,000	1,180	0	2,125	33,292		0
debt issuance costs																																											0	0	28,186	-58,326
reclassification of equity issuance costs																																								0
non-cash deferred financing fees																																								-33,176
accrued debt issuance costs
noncash deferred financing fees
end of term liability for oxford note payable
proceeds from hercules note payable, net of fees																																											5,000,000	0	0	4,850,000
prepayment penalty of early extinguishment of hercules note payable
debt issuance costs of oxford note payable
proceeds from short-term investments
net increase in cash and
cash equivalents																																										-634,840				368,482	20,769,434	-2,273,436	-2,667,038	-2,215,155
net proceeds from issuance of common stock
end of term liability for hercules note payable																																															0	0	0	26,500
proceeds from sale of short-term investments																																														732,143
payment of equity issuance costs																																															-357,990			-71,514	-71,514	-36,140	-296,398	-933,957
net increase(decrease) in cash and
non-cash interest expense related to notes payable
loss on sale of equipment
short-term investments
proceeds from hercules note payable																																															0	0
repurchase of common stock
repayments of notes payable
net increasein cash and
conversion of notes payable and interest in private placement
stock retained by stockholders of shell company																																																			0
proceeds from issuance of common stock, net of note
payable conversion
payments on notes payable																																																				0	0	-200,000
conversion of notes payable and accrued interest into common stock																																																				0	0	262,740
stock issued to shell company																																																					0	53
increase in:
changes in assets and liabilities:
proceeds from hercules debt note payable																																																		1,000,000
conversion of notes payable and accrued interest into
common stock
reclassification of equity issuance costs to additional
paid in capital
amortization of debt discount and beneficial conversion charge
noncash interest expense related to notes payable
loss on sale of inventory
loss on disposal of equipment
restricted cash
cash flows from investing activities purchase of equipment
cash flows from financing activities
proceeds from the issuance of common stock, net of note payable conversion
proceeds from note payable, net of fees
proceeds from convertible notes payable
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year
interest paid
supplemental disclosures:
noncash financing activities:
preferred stock issued upon note payable and interest conversion
equity issuance costs, accrued and not paid
issuance of common stock through the cashless exercise of warrants
end of term liability for note payable
loss on sale of research and development inventory
stock based compensation																																																				208,195	154,095	46,254
purchase of equipment																																																				-27,370
proceeds from issuance of common stock, net of note payable conversion																																																				0	0	17,287,288
cash and cash equivalents – beginning of period																																																				0	0	87,771
cash and cash equivalents – end of period																																																				-2,167,391	-1,352,040	14,239,828
loss-on sale of research and development inventory
increase in inventories																																																						-27,943
increase in accounts receivable
increase in prepaid expenses																																																						-369,217
decrease in other assets
increase in accounts payable																																																						-794,562
increase in accrued expenses																																																						-298,064	900	-600
increase in accrued interest																																																						1,959
decrease in deferred rent liability																																																						-5,547
1.
cash flows from operating activities
changes in operating assets and liabilities
proceeds received from subscribers of
contributed capital																																																							0	6,500
cash and cash equivalents at beginning of period																																																							0	0
cash and cash equivalents at end of period																																																							-3,910	2,080
supplemental disclosure of cash flows information
income taxes
exhibit
31.1
31.2
32.1
32.2
proceeds received from subscribers of common stock
r&r acquisition vi, inc.
notes to condensed financial statements
december 31, 2009
10.1

We provide you with 20 years of cash flow statements for ADMA Biologics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ADMA Biologics stock. Explore the full financial landscape of ADMA Biologics stock with our expertly curated income statements.

The information provided in this report about ADMA Biologics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.